TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 01/25/24

2024-01-25 17:09:29 ET More on Cognizant Technology Cognizant: 2024 Is Unlikely To Be A Repeat Of 2023 Cognizant Can Go Up And Down, But I Say 'Hold' Cognizant: I Stay Cautious For Now Read the full article on Seeking Alpha For further details see: ...

Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation PR Newswire Cognizant will support Takeda's ambition to modernize technology capabilities TEANECK, N.J. , Jan. 25, 2024 /PRNewswire/ -- C...

2024-01-23 14:30:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Google “How important is sleep?” and you get three billion results . So, it stands to reason that the booming sleep industry isn’t a fad. If that’s the case, inv...

2024-01-21 13:30:00 ET Pharmaceutical companies would be wise to pay attention to developing new treatments for ADHD as there is a demand for improved drugs in the space. Currently, the medications of choice for the condition are stimulant drugs, such as Takeda's ( NYSE: TAK ) V...

Achieved Global Recognition and Top Employer Certification in 24 Countries from Top Employers Institute Global Recognition Reinforces Commitment to Creating an Exceptional People Experience Takeda ( TSE:4502/NYSE:TAK ) today announced that for the sev...

2024-01-16 12:40:46 ET More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation ...

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous Immunoglobulin (SCIG) Infusion to Treat CIDP, Can Be Administered by a Healthcare Professional or Self-Administered after Appropriate Training ...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-03 03:21:42 ET Summary Results from phase 3 KONFIDENT trial, using sebetralstat for on-demand treatment of patients with HAE, expected early 2024. Upon primary endpoint of PGI-C score being met, NDA filing of sebetralstat for HAE expected 1st half of 2024; European and Jap...

2023-12-29 12:01:36 ET More on Pfizer The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Pfizer: Buy The Panic Pfizer in 2024: What to expect? P...